|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The digestive enzymes market was valued at approximately USD 769.87 million in 2020, and it is expected to reach USD 1245.92 million by 2026, registering a CAGR of 8.35% over the forecast period, 2021-2026.
The novel coronavirus has significantly impacted all industries, including food and beverage, automotive, chemicals, and many others. This pandemic has resulted in mass production shutdowns and supply chain disruptions, which have affected the global economy.
Factors such as the rising geriatric population, the rising prevalence of gastrointestinal disorders, increasing awareness about GI health, and focus on preventive health management are contributing to the market growth. The global population is aging rapidly, owing to reduced birth rates and rising life expectancy. The demographic trend toward an elderly population represents a rising need for the management of disorders, such as GI tract obstructions. According to the report "World Ageing Population, 2019", the older population of age 65 years and above accounted for approximately 702.9 million all around the world, and it is expected to reach around 1,548.9 million. The secretion of digestive enzymes usually reduces with age that contributes to high levels of gastric discomfort, lower digestion rates, reduced food consumption, and/or a variety of other GI disorders. Therefore, with the rising elderly population, the market for digestive enzymes is expected to grow over the forecast period.
Digestive supplements containing micronutrients and vitamins C and D are safe, have low cost, and are an effective way of helping the immune system fight off COVID-19 from other acute respiratory tract diseases. Due to this, the demand for digestive supplements has increased in the market. At this period of time, everyone is susceptible to becoming a carrier of COVID-19, but it is especially affecting those aged above 60 years who have low immune systems. Health organizations across the country are reporting the best practices to limit transmission and advising citizens on ways to enhance their immune systems. These suggestions include getting good sleep, maintaining a healthy diet, exercising moderately, and taking digestive/nutritional supplements. Thus, the COVID-19 pandemic is expected to have a positive impact on the market due to the rising usage of digestive supplements and increasing awareness among people regarding preventive disease management.
Scope of the Report
Digestive enzymes represent a group of enzymes secreted by the digestive organs to break down complex macromolecules into their constituents to facilitate their absorption by the body. Several digestive enzymes are commercially available as dietary supplements and for the management of digestive disorders.
The digestive enzymes market is segmented by enzyme type (carbohydrase, protease, lipase, and other enzyme types), origin (animal, microbial, and plant), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Enzyme Type|
|Other Enzyme Types|
Key Market Trends
The Animal Origin Sub-segment Captured the Largest Market Share and is Expected to do the Same Over the Forecast Period
The demand for nutraceuticals and functional foods is expected to witness an upward surge owing to consumers opting for immunity-boosting supplements during the COVID-19 pandemic. Furthermore, a decline in the consumption of poultry, meat, and seafood products across the globe is expected to increase the demand for plant- and animal-based digestive supplements in the near future.
The animal origin sub-segment holds a significant market share in the origin segment and is expected to continue the same trend over the forecast period.
The major factors responsible for the growth of this segment include the efficiency of these animal-derived enzymes in various diseases or conditions, such as pancreatitis, exocrine pancreatic insufficiency, and pancreatic cancer. Hence, the increasing burden of these diseases may positively influence market growth.
According to Cancer Research UK, new cases for pancreatic cancer accounted for almost 10,257 in the United Kingdom for 2015-2017. The animal-based enzyme is currently preferred as standard care of treatment for these disorders due to its similar pathophysiology of animals and humans. For instance, the pancreatic pathophysiology of hogs is much similar to that of humans. However, ethical issues associated with animal origin products in some consumers are expected to hamper the segment's growth.
Many key players are involved in various growth strategies, such as collaborations, partnerships, agreements, and mergers and acquisitions that are expected to drive the market. In May 2020, Nestlé Health Science (NHSc) announced the successful completion of the asset purchase of Zenpep and Viokace, expanding NHSc’s portfolio. ZENPEP and VIOKACE, available in the United States, are a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency. Owing to the aforementioned factors, the animal origin sub-segment is expected to witness significant growth during the forecast period.
To understand key trends, Download Sample Report
North America Captured the Largest Market Share and is Expected to Retain its Dominance
In research, it has been found that digestive supplements are helpful in boosting digestion, thereby boosting the immune system. Due to this new trend, the demand for digestive supplements has increased highly. The demand for dietary supplements is increasing as due to the lockdown, gym facilities, jogging parks, and walking places are shut. People are less physically active due to the pandemic, which leads to indigestion problems. Thus, digestive supplements help the body break down food compounds and increase nutrient absorption, relieving symptoms of indigestion in the process.
North America emerged as the largest regional market in terms of revenue. The increasing prevalence of chronic gastrointestinal diseases, rapidly aging population, growing demand for preventive medicine, and the presence of major market players are the primary factors contributing to the large market size.
According to the US Census Bureau, in 2019, the geriatric population in the United States was recorded at approximately 52 million. Furthermore, in 2019, around 14.8 million people were diagnosed with ulcers in the United States, according to the Centers for Disease Control and Prevention.
Apart from the high prevalence of GI disorders, the changing lifestyles, unhealthy eating habits, and high disposable income are contributing to the high growth rate. On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period.
To understand geography trends, Download Sample Report
There is the presence of major market players, such as Zeus Biotech Limited, Klaire Labs, Amway Corporation, AbbVie Inc., and Biotics Research Corporation. The market for digestive enzymes is characterized by robust competition owing to the presence of numerous small and large manufacturers. In order to retain their market shares from getting dented and bolster their positions, well-established players are banking on product innovations by investing in research and development. Such companies are also forming partnerships with retail chain companies to increase their sales and revenues. The increasing innovation and rise in investments for various public and private organizations are expected to intensify the industry rivalry across the world.
In March 2020, DuPont launched Bonlacta, an enzyme for the lactose-free dairy market in North America. It is fast-acting under refrigeration conditions and can withstand high temperatures to enable new, optimized processes with even faster lactose hydrolysis targets.
In March 2020, Klaire Labs launched Ther-biotic Synbiotic, the next-evolution, shelf-stable combination of prebiotic and probiotics strains, in the United States.
Table of Contents
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Rising Prevalence of Gastrointestinal Disorders
4.2.3 Increasing Awareness about GI Health and Focus on Preventive Health Management
4.3 Market Restraints
4.3.1 Perception of Probiotic and Prebiotic Products as Alternatives to Digestive Enzymes
4.3.2 Stringent Regulatory Policies
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Enzyme Type
5.1.4 Other Enzyme Types
5.2 By Origin
5.3 By Geography
5.3.1 North America
184.108.40.206 United States (By Enzyme Type and Origin)
220.127.116.11 Canada (By Enzyme Type and Origin)
18.104.22.168 Mexico (By Enzyme Type and Origin)
22.214.171.124 Germany (By Enzyme Type and Origin)
126.96.36.199 United Kingdom (By Enzyme Type and Origin)
188.8.131.52 France (By Enzyme Type and Origin)
184.108.40.206 Italy (By Enzyme Type and Origin)
220.127.116.11 Spain (By Enzyme Type and Origin)
18.104.22.168 Rest of Europe (By Enzyme Type and Origin)
22.214.171.124 China (By Enzyme Type and Origin)
126.96.36.199 Japan (By Enzyme Type and Origin)
188.8.131.52 India (By Enzyme Type and Origin)
184.108.40.206 Australia (By Enzyme Type and Origin)
220.127.116.11 South Korea (By Enzyme Type and Origin)
18.104.22.168 Rest of Asia-Pacific (By Enzyme Type and Origin)
5.3.4 Middle-East and Africa
22.214.171.124 GCC (By Enzyme Type and Origin)
126.96.36.199 South Africa (By Enzyme Type and Origin)
188.8.131.52 Rest of Middle-East and Africa (By Enzyme Type and Origin)
5.3.5 South America
184.108.40.206 Brazil (By Enzyme Type and Origin)
220.127.116.11 Argentina (By Enzyme Type and Origin)
18.104.22.168 Rest of South America (By Enzyme Type and Origin)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Amway Corporation
6.1.3 AST Enzyme
6.1.4 Biotics Research Corporation
6.1.5 Country Life LLC
6.1.7 Enzymes Inc.
6.1.8 Garden of Life Inc.
6.1.9 Integrative Therapeutics
6.1.10 Klaire Labs
6.1.12 National Enzyme Company
6.1.13 Nestle SA
6.1.15 Zeus Biotech Limited
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Digestive Enzymes Market market is studied from 2018 - 2026.
What is the growth rate of Global Digestive Enzymes Market ?
The Global Digestive Enzymes Market is growing at a CAGR of 8.35% over the next 5 years.
What is Global Digestive Enzymes Market size in 2018?
The Global Digestive Enzymes Market is valued at 769 Million USD in 2018.
What is Global Digestive Enzymes Market size in 2026?
The Global Digestive Enzymes Market is valued at 1245 Million USD in 2026.
Which region has highest growth rate in Global Digestive Enzymes Market ?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Digestive Enzymes Market ?
North America holds highest share in 2020.
Who are the key players in Global Digestive Enzymes Market ?
Amway Corporation, AbbVie Inc., Biotics Research Corporation, Klaire Labs, Zeus Biotech Limited are the major companies operating in Global Digestive Enzymes Market .